A phase I, randomized, open-label, single-dose, 3-period crossover study to evaluate the drug-drug interaction between ZX008 (fenfluramine HCl oral solution) and a regimen of stiripentol, clobazam, and valproate in healthy subjects
Authors:
- Brooks BoydBBBrooks Boyd
- Steven SmithSSSteven Smith
- Arnold GammaitoniAGArnold Gammaitoni
- Bradley S. GalerBGBradley S. Galer
- Gail M. FarfelGFGail M. Farfel
- 1 January 2019
- journal article
- research article
- Published by Dustri-Verlag Dr. Karl Feistle in Int. Journal of Clinical Pharmacology and Therapeutics
- Vol. 57 (01) , 11-19
Abstract
Phase I, open-label, randomized, single-dose, 3-period crossover study assessing pharmacokinetics (PK) and safety of ZX008, a liquid oral formulation of fenfluramine (FFA) under development for adjunctive treatment of Dravet syndrome and Lennox-Gastaut syndrome, administered with and without a combined antiepileptic drug (AED) regimen of stiripentol (STP), valproate (VPA), and clobazam (CLB) (STP regimen). 26 healthy adults were administered the following treatments: ZX008 0.8 mg/kg; STP 3,500 mg, CLB 20 mg, VPA 25 mg/kg (max. 1,500 mg); and ZX008 0.8 mg/kg + STP regimen. Dose periods were 17 days apart. Blood samples were obtained for 72 hours after drug administration and used to calculate non-compartmental PK parameters. Statistical bioequivalence-type analysis demonstrated ZX008 had no significant impact on the PK of any drug in the STP regimen, while the STP regimen moderately affected FFA PK. The 3-drug combination increased the geometric mean Cmax, AUC0-t, and AUC0-inf of FFA while reducing the Cmax and AUC0-t of its major metabolite, norfenfluramine (norFFA). Adverse events (AEs) were mild to moderate and resolved spontaneously. ZX008 + STP regimen co-administration to healthy adult subjects modestly impacted the number but not severity of AEs. Results show that the STP regimen had a moderate impact on FFA and norFFA PK and ZX008 had no significant impact on the 3 STP regimen drugs. ZX008 would not be expected to alter the clinical response of patients to this regimen by means of an effect on PK. When administering these drugs together, a downward dose adjustment of ZX008 may be warranted. .Keywords
This publication has 19 references indexed in Scilit:
- Efficacy and safety of felbamate in children with refractory epilepsyEuropean Journal of Paediatric Neurology, 2014
- Evidence for a Role of Transporter-Mediated Currents in the Depletion of Brain Serotonin Induced by Serotonin Transporter SubstratesNeuropsychopharmacology, 2013
- Successful use of fenfluramine as an add‐on treatment for Dravet syndromeEpilepsia, 2012
- IN VITRO AND IN VIVO INHIBITORY EFFECT OF STIRIPENTOL ON CLOBAZAM METABOLISMDrug Metabolism and Disposition, 2006
- Functional characterization of agonists at recombinant human 5‐HT2A, 5‐HT2B and 5‐HT2C receptors in CHO‐K1 cellsBritish Journal of Pharmacology, 1999
- The influence of the sparteine/debrisoquine genetic polymorphism on the disposition of dexfenfluramineBritish Journal of Clinical Pharmacology, 1996
- Mechanisms of effects of d-Fenfluramine on brain serotonin metabolism in rats: Uptake inhibition versus releasePharmacology Biochemistry and Behavior, 1988
- Plasma concentrations of clobazam and its N-desmethyl metabolite; protection against pentetrazol-induced convulsions in miceJournal of Pharmacy and Pharmacology, 1984
- Enhancement of GABA binding by benzodiazepines and related anxiolyticsEuropean Journal of Pharmacology, 1983
- Brain concentrations of clobazam and N-desmethylclobazam and antileptazol activityJournal of Pharmacy and Pharmacology, 1980